{
    "2021-04-02": [
        [
            {
                "time": "2023-10-18",
                "original_text": "AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Supplemental New Drug Application",
                        "Moderate to Severe Atopic Dermatitis",
                        "Extension of Review"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}